Trial Search Results

A Pilot Study of Autologous T-Cell Transplantation With Vaccine Driven Expansion of Anti-Tumor Effectors After Cytoreductive Therapy in Metastatic Pediatric Sarcomas

This is a single arm study.

The tumor specimen is analyzed for the presence of a fusion protein which corresponds to available peptides. Patients undergo T cell harvest 10 days after an initial priming peptide-pulsed antigen presenting cell (APC) vaccine is performed.

Fresh APCs are utilized for initial priming vaccination. All subsequent vaccinations will use cryopreserved APCs. Minimum number of APCs administered per vaccination is 100,000/kg and maximum is 100,000,000/kg.

Patients undergo cytoreductive therapy for the treatment of their particular malignancy. This therapy usually consists of multiagent chemotherapy in the context of a separate protocol.

Following chemotherapy, infusion of harvested T cells followed by infusion of peptide-pulsed APC vaccinations occurs every 6 weeks for a total of 3 post-priming vaccinations. Influenza vaccine is administered by intramuscular injection concurrent to peptide-pulsed APC vaccines.

Interleukin -2 (IL-2) is administered as a continuous intravenous (IV) infusion for 4 days/week for 3 successive weeks starting on the same day as T cell /peptide-pulsed infusions.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

National Cancer Institute (NCI)

Stanford Investigator(s):

Intervention(s):

  • Biological: therapeutic autologous dendritic cells
  • Drug: indinavir sulfate
  • Procedure: peripheral blood stem cell transplantation

Phase:

Phase 2

Eligibility


- INCLUSION CRITERIA:

Patients with fusion protein bearing, metastatic malignancies of the following histologic
subtypes are eligible for evaluation for treatment on this protocol: alveolar
rhabdomyosarcoma (AR), and Ewing's sarcoma family of tumors (ESFT) which includes
classical, atypical and extraosseous Ewing's sarcoma, peripheral primitive neuroectodermal
tumors, peripheral neuroepithelioma, primitive sarcoma of bone, and ectomesenchymoma.
Eligibility will not be confirmed until the presence of a tumor-specific fusion protein is
documented by reverse transcription polymerase chain reaction (RT-PCR) which corresponds to
one of the tumor-specific peptides available for vaccination.

Patients with Stage IV or metastatic disease are eligible to be enrolled on study at the
time of initial presentation with tumor, prior to any cytoreductive therapy.

Alternatively, patients who have recurrent disease, but who have been remotely treated
(completed all antineoplastic therapy greater than or equal to one year prior to enrollment
for patients who are greater than 5 years of age, or completed all antineoplastic therapy
greater than 6 months prior to enrollment for patients who are less than or equal to 5
years of age), are also eligible for enrollment prior to any subsequent cytoreductive
therapy.

Patients who have received cytoreductive therapy for Stage IV or metastatic disease may be
enrolled at the time of completion of cytoreductive therapy if an apheresis specimen is
available which was collected and processed prior to cytotoxic therapy according to the
guidelines described in the protocol Section 3.2.2.

Such products will have been obtained by apheresis at the Clinical Center, National
Institutes of Health (NIH), with informed consent administered as per protocol 98-C-37,
97-C-0050 or as described on standard government request form 2626 for invasive procedures.

Patients must be less than or equal to 35 years at the time of initial diagnosis of
alveolar rhabdomyosarcoma or ESFT, weight greater than 10 kg at the time of apheresis.
Patients between 10-15 kg must be approved by the apheresis unit in the Department of
Transfusion Medicine (DTM) prior to enrollment on the protocol.

All patients or their legal guardians must give written informed consent indicating their
understanding of the investigational nature and risks of the study.

Patients must have adequate renal function (serum creatinine (Cr) less than 1.5 mg/dl or
creatinine clearance (Cr Cl), greater than 60 ml/min./1.73 m^2 and liver function
(transaminases less than 3 times normal, bilirubin less than 2.0 mg/dl). Patients will not
be excluded based upon abnormal hepatic function which is related to hepatic involvement by
tumor.

For remotely treated patients, a CD4 count of greater than or equal to 400 cells/mm^3 is
required.

EXCLUSION CRITERIA:

Women who are pregnant or lactating.

Patients with human immunodeficiency virus infection due to confounding effects on immune
function.

Patients with hepatitis B or hepatitis C infection will be excluded due to the untoward
risks to personnel working with blood specimens.

Patients who require daily oral corticosteroid therapy for any underlying disease will be
excluded.

Topical or inhaled corticosteroids are permitted.

Patients who are allergic to eggs, egg products, or thimerosal, or have a history of
Guillain-Barre syndrome may be enrolled on study but are ineligible to receive the
influenza vaccine.

Ages Eligible for Study

5 Years - 35 Years

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Not Recruiting